Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$8.38	$8.90	$6.01 ▼ $11.31	$1.76B	1.1	3.80 million shs	1.33 million shs
BSTC BioSpecifics Technologies	$88.53	$88.47	$42.00 ▼ $89.15	$650.25M	0.24	61,105 shs	N/A
CLDX Celldex Therapeutics	$22.02 +5.4%	$22.07	$14.40 ▼ $47.00	$1.46B	1.22	980,142 shs	2.43 million shs
FOLD Amicus Therapeutics	$7.60 +2.7%	$6.29	$5.51 ▼ $12.65	$2.34B	0.53	3.88 million shs	3.42 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	+1.21%	-1.76%	-1.64%	-19.35%	+7.16%
BSTC BioSpecifics Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
CLDX Celldex Therapeutics	-13.03%	-16.41%	-5.30%	+2.55%	-41.58%
FOLD Amicus Therapeutics	+0.82%	+2.92%	+22.31%	+18.21%	-37.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.1866 of 5 stars	3.5	2.0	0.0	4.2	2.6	2.5	0.6
BSTC BioSpecifics Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	1.4885 of 5 stars	3.4	3.0	0.0	0.0	1.1	0.0	0.0
FOLD Amicus Therapeutics	4.3118 of 5 stars	3.4	2.0	0.0	4.3	3.5	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.90	Moderate Buy	$16.70	99.28% Upside
BSTC BioSpecifics Technologies	0.00	N/A	N/A	N/A
CLDX Celldex Therapeutics	2.78	Moderate Buy	$46.67	111.93% Upside
FOLD Amicus Therapeutics	2.80	Moderate Buy	$16.22	113.45% Upside

Current Analyst Ratings Breakdown

Latest BSTC, FOLD, BCRX, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	CLDX Celldex Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$44.00 ➝ $38.00
8/20/2025	CLDX Celldex Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$56.00 ➝ $48.00
8/20/2025	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $62.00
8/20/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $42.00
8/4/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
7/17/2025	FOLD Amicus Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
7/1/2025	BCRX BioCryst Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	3.90	N/A	N/A	($2.01) per share	-4.17
BSTC BioSpecifics Technologies	$38.19M	17.03	$3.38 per share	26.18	$18.42 per share	4.81
CLDX Celldex Therapeutics	$7.02M	208.31	N/A	N/A	$9.87 per share	2.23
FOLD Amicus Therapeutics	$571.16M	4.10	N/A	N/A	$0.66 per share	11.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.18	N/A	N/A	1.88	-6.41%	N/A	-1.78%	11/3/2025 (Estimated)
BSTC BioSpecifics Technologies	$24.47M	$3.33	37.51	17.60	N/A	47.43%	14.81%	14.46%	N/A
CLDX Celldex Therapeutics	-$157.86M	-$3.01	N/A	N/A	N/A	-3,446.88%	-27.61%	-26.20%	11/5/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.12	N/A	17.67	N/A	-6.67%	-5.07%	-1.23%	11/5/2025 (Estimated)

Latest BSTC, FOLD, BCRX, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	CLDX Celldex Therapeutics	-$0.86	-$0.85	+$0.01	-$0.85	$1.13 million	$0.73 million
8/4/2025	Q2 2025	BCRX BioCryst Pharmaceuticals	$0.03	$0.15	+$0.12	$0.02	$149.59 million	$163.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BSTC BioSpecifics Technologies	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.25	2.22
BSTC BioSpecifics Technologies	N/A	66.24	66.24
CLDX Celldex Therapeutics	N/A	19.67	19.67
FOLD Amicus Therapeutics	1.92	3.21	2.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
BSTC BioSpecifics Technologies	60.34%
CLDX Celldex Therapeutics	N/A
FOLD Amicus Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	5.10%
BSTC BioSpecifics Technologies	15.70%
CLDX Celldex Therapeutics	4.40%
FOLD Amicus Therapeutics	2.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.92 million	199.21 million	Optionable
BSTC BioSpecifics Technologies	7	7.35 million	N/A	Not Optionable
CLDX Celldex Therapeutics	150	66.41 million	63.49 million	Optionable
FOLD Amicus Therapeutics	480	308.24 million	301.46 million	Optionable

BSTC, FOLD, BCRX, and CLDX Headlines

Recent News About These Companies

Aberdeen Group plc Acquires 205,834 Shares of Amicus Therapeutics, Inc. $FOLD

August 21 at 4:18 AM | marketbeat.com

Amicus Therapeutics, Inc. $FOLD Stock Position Increased by Algert Global LLC

August 20 at 6:47 AM | marketbeat.com

Vanguard Group Inc. Sells 208,342 Shares of Amicus Therapeutics, Inc. $FOLD

August 20 at 3:17 AM | marketbeat.com

Nuveen LLC Makes New $28.74 Million Investment in Amicus Therapeutics, Inc. $FOLD

August 19 at 4:44 AM | marketbeat.com

The Association of American Physicians and Surgeons Filed an Amicus Brief in the Ninth Circuit in Support of Restoring California's Religious Exemption to Vaccination

August 18 at 2:47 PM | globenewswire.com

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stake Boosted by Deutsche Bank AG

August 17, 2025 | marketbeat.com

Entropy Technologies LP Acquires Shares of 38,790 Amicus Therapeutics, Inc. (NASDAQ:FOLD)

August 16, 2025 | marketbeat.com

Amicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer

August 14, 2025 | tipranks.com

Connor Clark & Lunn Investment Management Ltd. Buys 483,698 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

August 14, 2025 | marketbeat.com

Amicus Therapeutics (NASDAQ:FOLD) Trading 9.3% Higher - Here's Why

August 5, 2025 | marketbeat.com

Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?

August 5, 2025 | zacks.com

Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?

August 5, 2025 | zacks.com

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

August 4, 2025 | finance.yahoo.com

187,897 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Jefferies Financial Group Inc.

August 4, 2025 | marketbeat.com

XTX Topco Ltd Has $871,000 Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

August 4, 2025 | marketbeat.com

Assetmark Inc. Trims Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

August 4, 2025 | marketbeat.com

Amicus Therapeutics Inc (FOLD) Q2 2025 Earnings Call Highlights: Sustained Revenue Growth ...

August 3, 2025 | gurufocus.com

Q2 2025 Amicus Therapeutics Inc Earnings Call Transcript

August 3, 2025 | gurufocus.com

Amicus Therapeutics (NASDAQ:FOLD) Upgraded to Buy at Wall Street Zen

August 3, 2025 | marketbeat.com

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 3, 2025 | marketbeat.com

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2025 Earnings Call Transcript

August 1, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BSTC, FOLD, BCRX, and CLDX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.38 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$8.38 -0.01 (-0.06%)

As of 04:18 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BioSpecifics Technologies NASDAQ:BSTC

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.

Celldex Therapeutics NASDAQ:CLDX

$22.02 +1.13 (+5.41%)

Closing price 04:00 PM Eastern

Extended Trading

$22.04 +0.02 (+0.09%)

As of 04:33 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Amicus Therapeutics NASDAQ:FOLD

$7.60 +0.20 (+2.70%)

Closing price 04:00 PM Eastern

Extended Trading

$7.56 -0.03 (-0.46%)

As of 05:15 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time